胸腔灌注重组人血管内皮抑制素注射液联合信迪利单抗治疗非小细胞肺癌恶性胸腔积液的临床研究  

Clinical Study on the Treatment of Malignant Pleural Effusion in Non small Cell Lung Cancer Using Intrathoracic Infusion of Recombinant Hu⁃man Endostatin Combined with Sintilimab

作　　者：褚小磊 王祥军 田州 CHU Xiaolei;WANG Xiangjun;TIAN Zhou(Department of Thoracic Surgery,Xinyi Hospital of Traditional Chinese Medicine,Xinyi 221400,Jiangsu,China)

机构地区：[1]新沂市中医医院胸外科,江苏新沂221400

出　　处：《系统医学》2024年第23期10-14,共5页Systems Medicine

摘　　要：目的 分析胸腔灌注重组人血管内皮抑制素注射液联合信迪利单抗治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)恶性胸腔积液(malignant pleural effusion, MPE)的临床疗效。方法 回顾性选取2021年3月-2023年6月新沂市中医医院收治的60例NSCLC合并MPE患者的临床资料,按照不同治疗方法分为对照组(24例)与治疗组(36例)。对照组采用重组人血管内皮抑制素注射液胸腔灌注治疗,治疗组在对照组的基础上联合信迪利单抗治疗。比较客观缓解率、疾病控制率、卡氏评分(Karnofsky Performance Status, KPS)、不良反应、无进展生存期及胸腔积液中血管内皮生长因子(vascular endothelial growth factor, VEGF)水平。结果两组客观缓解率、疾病控制率、不良反应率及无进展生存期比较,差异无统计学意义(P均>0.05)。治疗组完全缓解率高于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组KPS评分为(75.23±8.11)分,高于对照组的(70.43±7.67)分,差异有统计学意义(t=2.294,P<0.05)。治疗后,治疗组胸腔积液VEGF水平低于对照组,差异有统计学意义(P均<0.05)。结论 胸腔内灌注重组人血管内皮抑制素注射液联合信迪利单抗治疗NSCLC所致MPE的效果明显,可减少胸腔积液量及VEGF表达水平,改善生活质量。Objective To analyze the clinical efficacy of thoracic infusion of recombinant human vascular endothelial inhibitor injection combined with sindilizumab in the treatment of malignant pleural effusion(MPE)in non-small cell lung cancer(NSCLC).Methods The clinical data of sixty patients with NSCLC combined with MPE admitted to Xinyi Traditional Chinese Medicine Hospital from March 2021 to June 2023 were retrospectively selected and divided into the control group(twenty-four cases)and the treatment group(thirty-six cases)according to different treatment meth⁃ods.The control group was treated with recombinant human vascular endothelial inhibitor injection by thoracic perfu⁃sion,and the treatment group was combined with sindilizumab on the basis of the control group.The objective remis⁃sion rate,disease control rate,Karnofsky Performance Status(KPS),adverse reactions,progression-free survival and vascular endothelial growth factor(VEGF)level in pleural effusion were compared between the two groups.Results There were no statistically significant differences in objective remission rate,disease control rate,adverse reaction rate and progression-free survival between the two groups(all P>0.05).The complete remission rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the KPS score of the treatment group was 75.23±8.11,which was higher than 70.43±7.67 of the control group,and the dif⁃ference was statistically significant(t=2.294,P<0.05).After treatment,the level of VEGF in pleural effusion of the treatment group were lower than those of the control group,and the differences were statistically significant(both P<0.05).Conclusion Intrathoracic instillation of recombinant human vascular endothelial inhibitor injection combined with sindilizumab for the treatment of MPE caused by NSCLC was effective in reducing the amount of pleural effusion and the level of VEGF expression,and improving the quality of life.

关 键 词：非小细胞肺癌 恶性胸腔积液 重组人血管内皮抑制素 信迪利单抗 

分 类 号：R734.2[医药卫生—肿瘤]